322 related articles for article (PubMed ID: 33409716)
21. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells.
Teixeira C; Pratt MA
Mol Endocrinol; 1997 Aug; 11(9):1191-202. PubMed ID: 9259311
[TBL] [Abstract][Full Text] [Related]
22. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
24. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.
Cortés J; Im SA; Holgado E; Perez-Garcia JM; Schmid P; Chavez-MacGregor M
Cancer Treat Rev; 2017 Dec; 61():53-60. PubMed ID: 29100169
[TBL] [Abstract][Full Text] [Related]
25. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Liu B; Chen D; Chen S; Saber A; Haisma H
Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
[TBL] [Abstract][Full Text] [Related]
26. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
Cetin B; Wabl CA; Gumusay O
Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
[TBL] [Abstract][Full Text] [Related]
27. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
28. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Goel S; Wang Q; Watt AC; Tolaney SM; Dillon DA; Li W; Ramm S; Palmer AC; Yuzugullu H; Varadan V; Tuck D; Harris LN; Wong KK; Liu XS; Sicinski P; Winer EP; Krop IE; Zhao JJ
Cancer Cell; 2016 Mar; 29(3):255-269. PubMed ID: 26977878
[TBL] [Abstract][Full Text] [Related]
29. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL; Ehmsen S; Terp MG; Portman N; Tuttolomondo M; Gammelgaard OL; Hundebøl MF; Kaminska K; Johansen LE; Bak M; Honeth G; Bosch A; Lim E; Ditzel HJ
Nat Commun; 2021 Aug; 12(1):5112. PubMed ID: 34433817
[TBL] [Abstract][Full Text] [Related]
30. Emerging Innovative Therapeutic Approaches Leveraging Cyclin-Dependent Kinase Inhibitors to Treat Advanced Breast Cancer.
Cruz M; Reinert T; Cristofanilli M
Clin Pharmacol Ther; 2018 Jun; 103(6):1009-1019. PubMed ID: 29226311
[TBL] [Abstract][Full Text] [Related]
31. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
Qie S; Yoshida A; Parnham S; Oleinik N; Beeson GC; Beeson CC; Ogretmen B; Bass AJ; Wong KK; Rustgi AK; Diehl JA
Nat Commun; 2019 Mar; 10(1):1296. PubMed ID: 30899002
[TBL] [Abstract][Full Text] [Related]
32. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
[TBL] [Abstract][Full Text] [Related]
33. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
[TBL] [Abstract][Full Text] [Related]
34. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Mancuso MR; Massarweh SA
Curr Probl Cancer; 2016; 40(2-4):95-105. PubMed ID: 27839747
[TBL] [Abstract][Full Text] [Related]
35. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.
Kwapisz D
Breast Cancer; 2018 Sep; 25(5):506-516. PubMed ID: 29700711
[TBL] [Abstract][Full Text] [Related]
36. Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ; Beach D; Shapiro GI
Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of resistance to estrogen receptor modulators in ER+/HER2- advanced breast cancer.
Zhang J; Wang Q; Wang Q; Cao J; Sun J; Zhu Z
Cell Mol Life Sci; 2020 Feb; 77(4):559-572. PubMed ID: 31471681
[TBL] [Abstract][Full Text] [Related]
39. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Li Z; Razavi P; Li Q; Toy W; Liu B; Ping C; Hsieh W; Sanchez-Vega F; Brown DN; Da Cruz Paula AF; Morris L; Selenica P; Eichenberger E; Shen R; Schultz N; Rosen N; Scaltriti M; Brogi E; Baselga J; Reis-Filho JS; Chandarlapaty S
Cancer Cell; 2018 Dec; 34(6):893-905.e8. PubMed ID: 30537512
[TBL] [Abstract][Full Text] [Related]
40. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.
Scheidemann ER; Shajahan-Haq AN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
